These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 6214206)

  • 1. Splenic alterations during mammary tumorigenesis: diverse effects on different immune parameters.
    Paul RD; Ghaffar A; Sigel MM; Charyulu V; Lopez DM
    Anticancer Res; 1981; 1(2):63-9. PubMed ID: 6214206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice.
    Buessow SC; Paul RD; Lopez DM
    J Natl Cancer Inst; 1984 Jul; 73(1):249-55. PubMed ID: 6610791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas.
    Fu Y; Paul RD; Wang Y; Lopez DM
    J Immunol; 1989 Dec; 143(12):4300-7. PubMed ID: 2592775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific suppressor cells induced by immunization with spleen cells from tumor-bearing animals.
    Huber SA; Bigi G; Lucas ZJ
    Cancer Res; 1980 Oct; 40(10):3477-83. PubMed ID: 6449281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the effector cells mediating an "innocent bystander" cytotoxicity reaction induced by a syngeneic mammary adenocarcinoma in mice.
    Paul RD; Padmanabhan R; Lopez DM
    Cancer Res; 1984 Oct; 44(10):4480-6. PubMed ID: 6467207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonspecific T-cell reactivity in mice bearing autochthonous tumors or early-generation transplanted spontaneous mammary tumors.
    Parthenais E; Haskill S
    J Natl Cancer Inst; 1979 Jun; 62(6):1569-74. PubMed ID: 312353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A granulocytosis-inducing tumor inhibits the production of B lymphocytes in murine bone marrow.
    Fülöp G; Lee MY; Rosse C
    J Immunol; 1985 Dec; 135(6):4266-72. PubMed ID: 3877765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic determinants in a virus-induced mouse mammary tumor recognized by cell-mediated immune assays.
    Lopez PF; Parks WP; Lopez DM
    J Natl Cancer Inst; 1984 Mar; 72(3):725-32. PubMed ID: 6199544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-11-induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice.
    Torroella-Kouri M; Keith JC; Ivanova M; Lopez DM
    Int J Oncol; 2003 Feb; 22(2):439-48. PubMed ID: 12527946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses.
    Watson GA; Lopez DM
    J Immunol; 1995 Sep; 155(6):3124-34. PubMed ID: 7673727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells from mammary tumor bearing mice do not exert natural killer activity but function as antibody dependent cellular cytotoxicity effectors.
    Rivera LM; Lopez DM
    Anticancer Res; 1993; 13(1):177-84. PubMed ID: 8476211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Langerhans cells from mice bearing a granulocyte macrophage-colony stimulating factor-producing mammary tumor display impaired accessory functions.
    Xie Y; Fernandez ME; Streilein JW; Lopez DM
    Anticancer Res; 1996; 16(1):9-16. PubMed ID: 8615675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of serial transplantation on the immunological-clinical correlates of BALB/cfC3H mouse mammary tumors.
    Hager JC; Miller FR; Heppner GH
    Cancer Res; 1978 Aug; 38(8):2492-500. PubMed ID: 667845
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity.
    Kuperman O; Fortner GW; Lucas ZJ
    J Immunol; 1975 Nov; 115(5):1282-7. PubMed ID: 1176776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of responses to tumor antigens and mouse mammary tumor virus in BALB/cCrgl and BALB/cfC3H mice.
    Lopez DM; Sigel MM; Charyulu VL
    J Natl Cancer Inst; 1981 Jan; 66(1):191-6. PubMed ID: 6256573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age- and sex-related differences in antibody formation and blastogenic responsiveness of splenocytes from RIII mice developing virus-induced mammary adenocarcinoma.
    Specter S; Friedman H
    J Natl Cancer Inst; 1981 Dec; 67(6):1347-51. PubMed ID: 6273637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T and B lymphocyte migration into syngeneic tumors.
    Elboim CM; Reinisch CL; Schlossman SF
    J Immunol; 1977 Mar; 118(3):1042-8. PubMed ID: 300384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.